Viewing nowCombinationOlmeduo Tablet 5/20 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.

MFDS item code 201404596 · Approved 2014.10.06 · Insurance code 670607110
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil.
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) ∘Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
The safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm or death to the fetus and neonate if taken during the second and third trimesters of pregnancy; therefore, discontinuation should occur immediately upon confirmation of pregnancy. It should not be used in patients with allergic reactions to this medication, severe liver impairment, severe aortic stenosis, biliary obstruction, patients on hemodialysis, those in a state of shock, or certain diabetic patients. Patients with fluid or salt depletion may experience hypotension, thus careful monitoring of their condition is required at the initiation of treatment, and appropriate measures should be taken as necessary. Care is needed particularly in patients with aortic stenosis as rapid vasodilation could lead to hypotension. Patients with heart failure or severe obstructive coronary artery disease may experience worsening heart conditions when taking this medication and should use it with caution. Patients with impaired renal function may be affected by this medication, necessitating regular monitoring of kidney function. Patients with liver impairment should also use this medication cautiously and observe liver function closely. During treatment with this medication, side effects such as dizziness, headache, hypotension, edema, and dyspepsia may occur, so if any abnormal symptoms arise, consultation with healthcare professionals is required. This medication should be avoided during pregnancy, and if breastfeeding, consideration should be given to discontinuing either breastfeeding or the medication due to potential transmission through breast milk, which could impact the infant. Safety and efficacy for pediatric patients under the age of 18 have not been established and is therefore not recommended. Elderly patients may be more sensitive to this medication due to reduced renal and liver function, and treatment should start at lower doses with careful dosage adjustments. Overdose may result in severe hypotension, vasodilation, tachycardia, and may require immediate medical attention. This medication should be stored in a tightly sealed container away from moisture, heat, and direct sunlight, out of reach of children. Additionally, there may be interactions with other medications, so it is imperative to inform healthcare professionals of all other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, at room temperature between 1°C and 30°C. Proper storage will help maintain the drug's effectiveness for a longer period.
White round film-coated tablet
28 tablets (14 tablets/PTP x 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.